E. Sally Ward

From Wikipedia, the free encyclopedia
Sally Ward
Born
Elizabeth Sally Ward
Alma materUniversity of Cambridge
AwardsRoyal Society Wolfson Research Merit Award (2018)
Scientific career
FieldsImmunology
Cancer Biology
Antibody Engineering
Antibody Therapeutics[1]
InstitutionsTexas A&M University
University of Texas Southwestern Medical Center
University of Cambridge
University of Southampton
ThesisMolecular genetics of an insectidal delta-endotoxin from Bacillus thuringiensis var israelensis. (1985)
Doctoral advisorDavid J. Ellar
Websitewww.wardoberlab.com/lab-members/sally-ward/ Edit this at Wikidata

Elizabeth Sally Ward FRS is a British physician who is Director of Translational Immunology at the Centre for Cancer Immunology in the University of Southampton.[1][2] She was elected Fellow of the Royal Society in 2022.[3]

Early life and education[edit]

Ward was an undergraduate student at the University of Cambridge, where she studied the Natural Sciences Tripos with a focus on biochemistry. She remained at Cambridge for her doctoral research, working under the supervision of David J. Ellar at Gonville and Caius College, Cambridge.[4][5][6] Her PhD research investigated the genetics of delta endotoxin from Bacillus thuringiensis israelensis.[7]

Research and career[edit]

Ward remained at Cambridge as a junior research fellow, working in both Gonville and Caius College and Sidney Sussex College, Cambridge.[8]

In 1990, Ward moved to the United States. She joined the University of Texas Southwestern Medical Center, where she was a member of the founding team of the Centre for Immunology. She was awarded various named chairs in Texas, including the Paul and Betty Meek-FINA Professorship. In 1996, Ward identified the Fc receptor, a regulator of Immunoglobulin G levels.[9] She moved to the Texas A&M University Health Sciences University in 2014.[9] In 2018, Ward returned to the United Kingdom, joining the University of Southampton as Professor of Molecular Immunology and Director of Translational Immunology.[10][11]

Ward works on antibody and protein engineering to treat autoimmune disease.[12] She makes use of in vivo studies to design novel anti-body therapies for the treatment of cancer. Her early identification of the Fc receptor has resulted in the development of FcRn antagonist technologies.[13][14] Ward has licensed these Abdegs (antibodies that enhance IgG degradation) to the pharmaceutical industry, resulting in anti-body therapeutics.[9][14][15]

Ward has developed advanced microscopies and image analysis techniques. She has demonstrated single molecule spectroscopy is capable of imaging single protein molecules at exceptional resolution. She uses multi-colour imaging to interrogate the cell surfaces. Using these approaches, Ward visualised the biological pathways intracellular endoscopes to the plasma membrane (and vice versa).[12] She has also pioneered open access software packages for miroscopy analysis.[12]

Awards and honours[edit]

Selected publications[edit]

  • Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli[16]
  • Localization accuracy in single-molecule microscopy"[17]
  • Multiple roles for the major histocompatibility complex class I- related receptor FcRn[18]
  • Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies[19]

References[edit]

  1. ^ a b E. Sally Ward publications indexed by Google Scholar Edit this at Wikidata
  2. ^ E. Sally Ward publications from Europe PubMed Central
  3. ^ a b Anon (2022). "Sally Ward FRS". royalsociety.org. London: Royal Society. Retrieved 2022-05-11.
  4. ^ Anon (2020). "Professor David Ellar (1939 - 2020)". cai.cam.ac.uk.
  5. ^ Susana Vilchez (3 December 2020). "A Tribute to a <i>Bacillus thuringiensis</i> Master: Professor David J. Ellar". Toxins. 12 (12). doi:10.3390/TOXINS12120764. ISSN 2072-6651. PMID 33287128. Wikidata Q104108938.
  6. ^ Anon (2018). "Cancer Institute Seminar Series - Prof Sally Ward". ucl.ac.uk. UCL Cancer Institute. Retrieved 2022-05-11.
  7. ^ Ward, Elizabeth Sally (1985). Molecular genetics of an insectidal delta-endotoxin from Bacillus thuringiensis var israelensis. cam.ac.uk (PhD thesis). University of Cambridge. OCLC 499855244. EThOS uk.bl.ethos.377842.
  8. ^ Anon. "Home". wardoberlab.com. WardOber Lab. Retrieved 2022-05-11.
  9. ^ a b c d "Sally Ward, Ph.D." antibodysociety.org. The Antibody Society. Retrieved 2022-05-11.
  10. ^ Anon (2019). "Lab Members". wardoberlab.com. WardOber Lab. Retrieved 2022-05-11.
  11. ^ "Interview with Sally Ward and Raimund Ober". southampton.ac.uk. Centre for Cancer Immunology. Retrieved 2022-05-11.
  12. ^ a b c Anon (2019). "Research Interests". wardoberlab.com. Retrieved 2022-05-11.
  13. ^ "SELECTBIO - High-Content and Phenotypic Screening Europe 2018 Speaker Biography". selectbiosciences.com. Retrieved 2022-05-11.
  14. ^ a b "More than two decades of UTSW research paves way for first-in-kind drug". utsouthwestern.edu. 3 January 2022. Retrieved 2022-05-11.
  15. ^ "Married scientists developing breakthrough cancer drugs urge people to Stand Up To Cancer". dailyecho.co.uk. Daily Echo. 14 October 2021. Retrieved 2022-05-11.
  16. ^ Ward ES; Güssow D; Griffiths AD; Jones PT; Winter G (1 October 1989). "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli". Nature. 341 (6242): 544–546. doi:10.1038/341544A0. ISSN 1476-4687. PMID 2677748. Wikidata Q35896400.
  17. ^ Raimund J. Ober; Sripad Ram; E. Sally Ward (1 February 2004). "Localization accuracy in single-molecule microscopy". Biophysical Journal. 86 (2): 1185–1200. doi:10.1016/S0006-3495(04)74193-4. ISSN 0006-3495. PMC 1303911. PMID 14747353. Wikidata Q34184690.
  18. ^ Ghetie V; Ward ES (1 January 2000). "Multiple roles for the major histocompatibility complex class I- related receptor FcRn". Annual Review of Immunology. 18: 739–766. doi:10.1146/ANNUREV.IMMUNOL.18.1.739. ISSN 0732-0582. PMID 10837074. Wikidata Q33932754.
  19. ^ Ober RJ; Radu CG; Ghetie V; Ward ES (1 December 2001). "Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies". International Immunology. 13 (12): 1551–1559. doi:10.1093/INTIMM/13.12.1551. ISSN 0953-8178. PMID 11717196. Wikidata Q34102657.